Clinical trial · Interventional
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia
A 12-week Double Blind, Placebo Controlled, Randomised Pilot Study Assessing Safety and Tolerability of Nutrifriend Cachexia in Patients Diagnosed With Non Small Cell Lung Cancer (NSCLC) With Involuntary Weight Loss
NCT02515032CI-TRIAL-00028652completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
SF-C002 is a pilot study in patients with newly diagnosed NSCLC suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of Nutrifriend Cachexia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Isocaloric placebo | Dietary Supplement | — | UNRESOLVED |
| Nutrifriend Cachexia | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- NF Cachexia
- description
- Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
- interventionNames
- Dietary Supplement: Nutrifriend Cachexia
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- An isocaloric placebo comparator
- interventionNames
- Dietary Supplement: Isocaloric placebo
Primary outcomes (1)
- measure
- Safety and tolerability assessed by (adverse events, concomitant medication and laboratory markers) of Nutrifriend Cachexia in patients with NSCLC
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * First-line standard chemotherapy as curative or palliative treatment for NSCLC * Will start the first cycle of standard chemotherapy * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 * Involuntary weight loss Exclusion Criteria: * Another invasive malignancy in the last 2 years. * Previous relapse of NSCLC within 2 years of randomisation * Other cachectic disorders such as renal or hepatic disorders
References
Publications (1)
- DERIVEDLaviano A, Calder PC, Schols AMWJ, Lonnqvist F, Bech M, Muscaritoli M. Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial. Nutr Cancer. 2020;72(3):439-450. doi: 10.1080/01635581.2019.1634746. Epub 2019 Jul 10. PMID 31290697